BioSpace News Archive

The world of dentistry continued to move ahead at a massive pace and is witnessing an increasing influx of advanced technologies.

ASLAN Pharmaceuticals announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis.

Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience

Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.

The board of directors of Medtronic plc on Friday, August 21, 2020, approved the fiscal year 2021 second quarter cash dividend of $0.58 per ordinary share, representing a 7 percent increase over the prior year.

KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® 9%.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that research on the Company has been initiated by André Uddin, Managing Director Healthcare at Mackie Research Capital Corporation with a speculative buy recommendation and a target price of $0.80/share.

Ortho Regenerative Technologies Inc., an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced the closing of a non-brokered $2.5 million private placement of units.

Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease